NYKD — Nykode Therapeutics ASA Cashflow Statement
0.000.00%
Last trade - 00:00- NOK771.96m
- -NOK394.62m
- $8.68m
Annual cashflow statement for Nykode Therapeutics ASA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 181 | -11.1 | -51 | -44.1 | -45.5 |
| Depreciation | |||||
| Non-Cash Items | 9.84 | 19.4 | 3.77 | -25.3 | -6.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -10.8 | -7.82 | 24.7 | -29.4 | -1.16 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 180 | 1.16 | -20.7 | -96.6 | -51.2 |
| Capital Expenditures | -0.099 | -0.872 | -2.67 | -1.9 | -0.071 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5.92 | 11.6 | 13.7 | 8.94 | 7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -6.02 | 10.8 | 11.1 | 7.04 | 6.93 |
| Financing Cash Flow Items | -0.045 | -0.131 | -0.24 | -0.215 | -0.179 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.289 | 20.4 | 0.36 | 44.6 | -1.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 174 | 32.4 | -9.84 | -43.8 | -47.2 |